Who We Are

President

Dr. Garry Morefield has been the President at VaxForm, LLC for 13 years. Prior to founding VaxForm, Dr. Morefield was the head of formulation and stability at Sanofi Pasteur. At Sanofi Pasteur he worked on a variety of bacterial and viral vaccine targets from pre-clinical development through clinical phases as well as marketed products. These included seasonal and pandemic influenza, pneumococcal and meningococcal conjugates, meningococcal group B, C. difficile, hepatitis B, inactivated polio, diphtheria, tetanus, pertussis as well as combination vaccine products. Dr. Morefield has additional experience with biodefense vaccine development while working at the United States Army Medical Research Institute of Infectious Disease. While there he participated in formulation development of Streptococcal enterotoxin B, anthrax, plague, and botulinum neurotoxin A vaccines. Additionally, he has particular expertise in adjuvant development and production including TLR and CTL agonists, squalene-based emulsions, and aluminum salts. Dr. Morefield is a recognized expert in aluminum adjuvants giving multiple talks at research conferences, private company workshops, and as an expert witness in patent prosecutions. 

Deputy Director, Process Development

Dr. Elodie Burlet brings over 8 years of experience in the research and development of vaccines to VaxForm. She has worked on the formulation development of a variety of vaccines targeting bacterial and viral pathogens, including Streptococcus pyogenes, Streptococcus Pneumoniae, Staphylococcus Aureus, Rabies, combination vaccine Diphtheria/Tetanus/Pertussis, HIV, Neisseria Meningitis, SARS-CoV-2, as well as immunotherapies targeting non-infectious diseases such as Alzheimer’s and cardiovascular diseases. Dr. Burlet also has extensive experience in aluminum adjuvants production and development, antigen fermentation and purification, assay development, and small-scale final drug product fill finish. 

Dr. Burlet was the technical lead on the SBIR Phase I NSF-funded project to develop orally administered DTaP vaccine using VaxForm’s patented oral delivery technology and is currently the Principal Investigator on another NSF-funded SBIR Phase I project supporting VaxForm’s latest vaccine developmental effort: an oral and thermally stable COVID-19 vaccine. 

Dr. Burlet received her Ph.D in Biochemistry and Molecular Biology from Louisiana State University Health Shreveport.